A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00396669|
Recruitment Status : Unknown
Verified March 2012 by VEINSHTEIN AVIV, Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : November 7, 2006
Last Update Posted : March 27, 2012
|Condition or disease||Intervention/treatment||Phase|
|Tobacco Use Disorder||Drug: Bupropion||Not Applicable|
Dopamine plays a critical role in nicotine(and other) addiction and this drug is known to release DA in brain areas mediating reward and motivational processes. Although imaging studies show that release of DA follows smoking, little is known regarding how common some genetic polymorphisms proposed to play a role in nicotine dependence (e.g. DRD2, DAT and the serotonin transporter or SERT) interact with smoking status (non-smoker, ex-smoker, light smoker, present smoker) and modulate individual differences in nicotine-induced DA release and dopamine receptor occupancy, in vivo. Individual differences in dopaminergic tone could result in an under-stimulation of reward circuits which could put subjects at greater risk for seeking drug stimulation (that releases DA) as a means to compensate for this deficit and to temporarily activate these reward circuits. The current proposal combines brain imaging and genomics towards unraveling the complex relationship between smoking phenotype and common polymorphisms. Understanding whether genetic factors contribute to inter-individual variability is crucial for interpreting imaging results in the context of disease pathology.
Nicotine dependence is a complex process including initiation of smoking, persistence and difficulty in quitting. By comparing receptor occupancy, nicotine-induced DA release, and common genetic polymorphisms across smoking behaviors we will better understand the complex interactions between genetic makeup, personality and the several stages of nicotine addiction.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers, Using 11 C Raclopride in Positron Emission Tomography (PET)|
|Study Start Date :||July 2007|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||July 2012|
|Experimental: Dopamine release||
We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
Brain imaging after treatment with Bupropion
Other Name: Zyban
- Dopamine D2 receptor occupancy before and after smoking a cigarette with nicotine [ Time Frame: 30 minutes ]
- Subjective measures of craving, anxiety and depression. [ Time Frame: 30 minutes ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00396669
|Contact: Aviv M Weinstein, Ph.D||00 972 2 email@example.com|
|Hadassah Medical Organization||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Hadas Lemberg, Ph.D 00 972 2 6777572 firstname.lastname@example.org|
|Principal Investigator: Aviv M Weinstein, Ph.D|
|Principal Investigator:||Aviv M Weinstein, Ph.D||Hadassah Medical Organization|
|Principal Investigator:||Moshe Bocher, M.D||Hadassah Medical Organization|